{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:20:25Z","timestamp":1750306825986,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7232192"],"award-info":[{"award-number":["7232192"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye and Vis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>A post hoc analysis of the STAR study, which was a 48-week, phase IV, multicenter randomized controlled multicenter clinical trial was performed. This study aims to identify the baseline factors associated with visual and anatomic changes over 48\u00a0weeks in the treatment of active polypoidal choroidal vasculopathy (PCV) with conbercept.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In the STAR study, 249 participants were randomized to either the 3\u2009+\u2009Q12W (3 monthly injections followed by injections every 12\u00a0weeks) or 3\u2009+\u2009TAE (3 monthly injections followed by treat and extend regimen) group. The association of 27 baseline factors with three outcomes\u2014changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and maximum retinal thickness (MRT) from baseline to 48\u00a0weeks\u2014was investigated using univariate regression analysis followed by multivariate linear regression analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The final multivariate model indicated that worse baseline BCVA (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), CRT\u2009\u2264\u2009400\u00a0\u03bcm (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), fewer polypoidal lesions (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and younger age at baseline (<jats:italic>P<\/jats:italic>\u2009=\u20090.04) were associated with greater BCVA gain at week 48. Higher CRT and MRT at baseline were associated with a greater reduction in CRT and MRT at week 48, separately (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01, respectively). Smaller pigment epithelial detachment (PED) volume at baseline was associated with greater reductions in CRT and MRT at week 48 (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). Eyes with relatively good BCVA (&gt;\u200973 letters) at baseline exhibited lower reductions in CRT and MRT at week 48 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01 and <jats:italic>P<\/jats:italic>\u2009=\u20090.02, respectively). At week 48, eyes with hemorrhagic PEDs showed greater reductions in CRT and MRT than those with fibrovascular PEDs (<jats:italic>P<\/jats:italic>\u2009=\u20090.02 and <jats:italic>P<\/jats:italic>\u2009=\u20090.03, respectively). Furthermore, eyes with shallow irregular or sharp-peaked PEDs exhibited greater reductions in CRT (both <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) and MRT (<jats:italic>P<\/jats:italic>\u2009=\u20090.01 and <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01, respectively) than those with multilobular PEDs from baseline to week 48.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In Chinese patients with PCV receiving intravitreal injections of conbercept, baseline characteristics, including age, BCVA, CRT, MRT, number of polypoidal lesions, PED volume, and PED types and morphology, served as predictors of visual and anatomical changes over 48\u00a0weeks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40662-025-00441-5","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T07:25:09Z","timestamp":1750231509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors in the treatment of polypoidal choroidal vasculopathy with conbercept: a post hoc analysis of the STAR study"],"prefix":"10.1186","volume":"12","author":[{"given":"Tsung-I.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6616-6596","authenticated-orcid":false,"given":"Xiaoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"1","key":"441_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","volume":"10","author":"LA Yannuzzi","year":"1990","unstructured":"Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10(1):1\u20138.","journal-title":"Retina"},{"issue":"1","key":"441_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang CE, Freund KB. Pachychoroid neovasculopathy. Retina. 2015;35(1):1\u20139.","journal-title":"Retina"},{"issue":"5","key":"441_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00417-021-05524-2","volume":"260","author":"NV Lassandro","year":"2022","unstructured":"Lassandro NV, Nicolai M, Arnaldi G, Franceschi A, Pelliccioni P, Cantini L, et al. Pachychoroid spectrum disease and choriocapillary flow analysis in patients with Cushing disease: an optical coherence tomography angiography study. Graefes Arch Clin Exp Ophthalmol. 2022;260(5):1535\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"7","key":"441_CR4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00417-010-1575-7","volume":"249","author":"J Hou","year":"2011","unstructured":"Hou J, Tao Y, Li XX, Zhao MW. Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2011;249(7):975\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"441_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","volume":"55","author":"Y Imamura","year":"2010","unstructured":"Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55(6):501\u201315.","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"441_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/bjophthalmol-2012-302652","volume":"97","author":"T Hikichi","year":"2013","unstructured":"Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, et al. Results of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2013;97(5):617\u201321.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"441_CR7","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/eye.2011.324","volume":"26","author":"HJ Cho","year":"2012","unstructured":"Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond). 2012;26(3):426\u201333.","journal-title":"Eye (Lond)"},{"issue":"5","key":"441_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/bjo.2007.135103","volume":"92","author":"TY Lai","year":"2008","unstructured":"Lai TY, Chan WM, Liu DT, Luk FO, Lam DS. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2008;92(5):661\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"441_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000477448","volume":"238","author":"Y Oshima","year":"2017","unstructured":"Oshima Y, Kimoto K, Yoshida N, Fujisawa K, Sonoda S, Kubota T, et al. One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: the APOLLO study. Ophthalmologica. 2017;238(3):163\u201371.","journal-title":"Ophthalmologica"},{"issue":"11","key":"441_CR10","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","volume":"135","author":"A Koh","year":"2017","unstructured":"Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, et al. Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial. JAMA Ophthalmol. 2017;135(11):1206\u201313.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"441_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000354072","volume":"231","author":"GT Kokame","year":"2014","unstructured":"Kokame GT, Yeung L, Teramoto K, Lai JC, Wee R. Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year. Ophthalmologica. 2014;231(2):94\u2013102.","journal-title":"Ophthalmologica"},{"issue":"4","key":"441_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.ajo.2013.05.024","volume":"156","author":"A Oishi","year":"2013","unstructured":"Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H, et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results. Am J Ophthalmol. 2013;156(4):644\u201351.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"441_CR13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453\u201364.","journal-title":"Retina"},{"issue":"6","key":"441_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1237\u201345.","journal-title":"Ophthalmology"},{"issue":"8","key":"441_CR15","doi-asserted-by":"publisher","first-page":"e911","DOI":"10.1111\/aos.13751","volume":"96","author":"P Lanzetta","year":"2018","unstructured":"Lanzetta P, Cruess AF, Cohen SY, Slakter JS, Katz T, Sowade O, et al. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies. Acta Ophthalmol. 2018;96(8):e911\u20138.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"441_CR16","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1136\/bjophthalmol-2011-300285","volume":"95","author":"H Koizumi","year":"2011","unstructured":"Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2011;95(11):1555\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"25","key":"441_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000011188","volume":"97","author":"R Mori","year":"2018","unstructured":"Mori R, Tanaka K, Yuzawa M. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity. Medicine (Baltimore). 2018;97(25):e11188.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"441_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00417-020-04988-y","volume":"259","author":"LH Ye","year":"2021","unstructured":"Ye LH, Cai Y, Shi X, Wong IYH, Qu JF, Zhao MW, et al. One-year results of intravitreal conbercept in treatment-naive subjects with polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259(6):1455\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"441_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1097\/IAE.0000000000002035","volume":"39","author":"Z Huang","year":"2019","unstructured":"Huang Z, Ding Q, Yan M, Lian H, Chen Z, Chen X, et al. Short-term efficacy of conbercept and ranibizumab for polypoidal choroidal vasculopathy. Retina. 2019;39(5):889\u201395.","journal-title":"Retina"},{"key":"441_CR20","doi-asserted-by":"publisher","first-page":"9340356","DOI":"10.1155\/2020\/9340356","volume":"2020","author":"Z Wang","year":"2020","unstructured":"Wang Z, Li M, Yao Y, Hu J, Tang J, Tang R, et al. Short-term results of switch from conbercept to bevacizumab or ranibizumab in eyes with persistent neovascular age-related macular degeneration. J Ophthalmol. 2020;2020:9340356.","journal-title":"J Ophthalmol"},{"issue":"5","key":"441_CR21","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/IAE.0000000000000875","volume":"36","author":"J Qu","year":"2016","unstructured":"Qu J, Cheng Y, Li X, Yu L, Ke X, AURORA Study Group. Efficacy of intravitreal injection of Conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the Aurora Study. Retina. 2016;36(5):926\u201337.","journal-title":"Retina"},{"issue":"21","key":"441_CR22","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.4103\/0366-6999.192779","volume":"129","author":"Y Cheng","year":"2016","unstructured":"Cheng Y, Shi X, Qu JF, Zhao MW, Li XX. Comparison of the 1-year outcomes of conbercept therapy between two different angiographic subtypes of polypoidal choroidal vasculopathy. Chin Med J (Engl). 2016;129(21):2610\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"441_CR23","first-page":"51","volume":"12","author":"HJ Qi","year":"2019","unstructured":"Qi HJ, Jin EZ, Zhao MW. One-year outcomes of intravitreal conbercept combined rescue therapy for polypoidal choroidal vasculopathy in a Chinese population: a real-life clinical data. Int J Ophthalmol. 2019;12(1):51\u20137.","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"441_CR24","doi-asserted-by":"publisher","first-page":"e327","DOI":"10.1111\/aos.15272","volume":"101","author":"X Li","year":"2023","unstructured":"Li X, Qu J, Su G, Yu S, Zhang Y, Sadda SV, et al. The comparison of two different strategies of intravitreal conbercept for polypoidal choroidal vasculopathy in Chinese patients results from a 48-week randomized phase 4 study: STAR study. Acta Ophthalmol. 2023;101(3):e327\u201337.","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"441_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ajo.2012.07.018","volume":"155","author":"H Koizumi","year":"2013","unstructured":"Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability. Am J Ophthalmol. 2013;155(2):305-13.e1.","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"441_CR26","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1097\/IAE.0000000000001758","volume":"38","author":"Y Yanagi","year":"2018","unstructured":"Yanagi Y, Ting DSW, Ng WY, Lee SY, Mathur R, Chan CM, et al. Choroidal vascular hyperpermeability as a predictor of treatment response for polypoidal choroidal vasculopathy. Retina. 2018;38(8):1509\u201317.","journal-title":"Retina"},{"issue":"4","key":"441_CR27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/IAE.0000000000002019","volume":"39","author":"J Lee","year":"2019","unstructured":"Lee J, Byeon SH. Prevalence and clinical characteristics of pachydrusen in polypoidal choroidal vasculopathy: multimodal image study. Retina. 2019;39(4):670\u20138.","journal-title":"Retina"},{"key":"441_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"K Liu","year":"2019","unstructured":"Liu K, Song Y, Xu G, Ye J, Wu Z, Liu X, et al. Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX Study. Am J Ophthalmol. 2019;197:156\u201367.","journal-title":"Am J Ophthalmol"},{"key":"441_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","volume":"204","author":"TY Wong","year":"2019","unstructured":"Wong TY, Ogura Y, Lee WK, Iida T, Chen SJ, Mitchell P, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study. Am J Ophthalmol. 2019;204:80\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"441_CR30","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1038\/s41433-020-0803-6","volume":"34","author":"KX Cheong","year":"2020","unstructured":"Cheong KX, Grewal DS, Teo KYC, Gan ATL, Jaffe GJ, Cheung GCM. The relationship between pigment epithelial detachment and visual outcome in neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Eye (Lond). 2020;34(12):2257\u201363.","journal-title":"Eye (Lond)"},{"issue":"4","key":"441_CR31","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652\u201360.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"441_CR32","doi-asserted-by":"publisher","first-page":"14943","DOI":"10.1038\/s41598-020-72030-6","volume":"10","author":"JH Kim","year":"2020","unstructured":"Kim JH, Kim JY, Lee DW, Kim CG, Kim JW. Fibrovascular pigment epithelial detachment in eyes with subretinal hemorrhage secondary to neovascular AMD or PCV: a morphologic predictor associated with poor treatment outcomes. Sci Rep. 2020;10(1):14943.","journal-title":"Sci Rep"},{"key":"441_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajo.2016.12.008","volume":"177","author":"EW Chan","year":"2017","unstructured":"Chan EW, Eldeeb M, Lingam G, Thomas D, Bhargava M, Chee CK. Quantitative changes in pigment epithelial detachment area and volume predict retreatment in polypoidal choroidal vasculopathy. Am J Ophthalmol. 2017;177:195\u2013205.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"441_CR34","doi-asserted-by":"publisher","first-page":"15662","DOI":"10.1038\/s41598-022-19400-4","volume":"12","author":"HJ Cho","year":"2022","unstructured":"Cho HJ, Jeon YJ, Yoon W, Yoon J, Kim J, Kim JW. Neovascular age-related macular degeneration without exudative recurrence over 24 months after initial remission. Sci Rep. 2022;12(1):15662.","journal-title":"Sci Rep"},{"issue":"10","key":"441_CR35","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.ophtha.2016.07.007","volume":"123","author":"D Sarraf","year":"2016","unstructured":"Sarraf D, London NJ, Khurana RN, Dugel PU, Gune S, Hill L, et al. Ranibizumab treatment for pigment epithelial detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR Study. Ophthalmology. 2016;123(10):2213\u201324.","journal-title":"Ophthalmology"},{"issue":"11","key":"441_CR36","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00417-011-1734-5","volume":"249","author":"A Mariani","year":"2011","unstructured":"Mariani A, Deli A, Ambresin A, Mantel I. Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2011;249(11):1635\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"441_CR37","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/bjophthalmol-2014-305606","volume":"99","author":"T Hikichi","year":"2015","unstructured":"Hikichi T, Kitamei H, Shioya S. Prognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2015;99(6):817\u201322.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"441_CR38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/IAE.0000000000001613","volume":"38","author":"S de Massougnes","year":"2018","unstructured":"de Massougnes S, Dirani A, Mantel I. Good visual outcome at 1 year in neovascular age-related macular degeneration with pigment epithelium detachment: factors influencing the treatment response. Retina. 2018;38(4):717\u201324.","journal-title":"Retina"},{"issue":"5","key":"441_CR39","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s10384-018-0605-6","volume":"62","author":"M Ogasawara","year":"2018","unstructured":"Ogasawara M, Koizumi H, Yamamoto A, Itagaki K, Saito M, Maruko I, et al. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;62(5):584\u201391.","journal-title":"Jpn J Ophthalmol"},{"issue":"2","key":"441_CR40","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ophtha.2022.09.013","volume":"130","author":"Q Bo","year":"2023","unstructured":"Bo Q, Zhang M, Chen J, Jia H, Shen M, Sun M, et al. Progression of polypoidal lesions associated with exudative recurrence in polypoidal choroidal vasculopathy. Ophthalmology. 2023;130(2):167\u201378.","journal-title":"Ophthalmology"},{"issue":"1","key":"441_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10384-014-0349-x","volume":"59","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Han SY, Kim HS, Lee TG, Kim JW. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2015;59(1):29\u201335.","journal-title":"Jpn J Ophthalmol"},{"key":"441_CR42","doi-asserted-by":"publisher","first-page":"852519","DOI":"10.3389\/fmed.2022.852519","volume":"9","author":"H Jia","year":"2022","unstructured":"Jia H, Lu B, Yuan Y, Yuan F, Li L, Song Y, et al. A randomized, controlled trial of treat-and-extend vs. pro re nata regimen for neovascular age-related macular degeneration. Front Med (Lausanne). 2022;9:852519.","journal-title":"Front Med (Lausanne)."}],"container-title":["Eye and Vision"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40662-025-00441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40662-025-00441-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40662-025-00441-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T08:02:21Z","timestamp":1750233741000},"score":1,"resource":{"primary":{"URL":"https:\/\/eandv.biomedcentral.com\/articles\/10.1186\/s40662-025-00441-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1186\/s40662-025-00441-5","relation":{},"ISSN":["2326-0254"],"issn-type":[{"value":"2326-0254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the principles of the Declaration of Helsinki and was approved by the Ethnic Committee of People\u2019s Hospital of Peking University (2014PHA044-02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}